1983•Acta Neurologica ScandinavicaRequires access

Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease

E Csanda, M Tárczy

Abstract

The experiences of a seven-year study on deprenyl in the treatment of Parkinson's disease are summarized. It was found that the main advantage of deprenyl was that it permitted the reduction of the dose of levodopa in optimally treated patients. In the initial stage of Parkinson's disease deprenyl is only partially sufficient as monotherapy. Deprenyl can administered successfully for correcting the "wearing off" effect.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 29 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Selegiline, Parkinson's disease, Levodopa, Medicine, Disease, Degenerative disease, Pharmacology, Internal medicine